The success of CheckMate 025 has invigorated the field of immunotherapy, encouraging further research into immune checkpoint inhibitors for various cancer types. Ongoing and future trials are exploring combination therapies, biomarkers for response prediction, and strategies to mitigate adverse effects, aiming to enhance the efficacy and safety of immunotherapy.
